WE’RE MOVING TOWARD PRECISION MEDICINE IN PSYCHIATRY.
WHAT WE DO
Clinical Implementation
Providing recommendations to physician on optimizing antidepressant and antipsychotic treatment using genetic testing
Pharmacogenomics
Exploring the effects of genetic variation on the response to psychotropic medications and side effects, such as antipsychotic-induced weight gain
Machine Learning
Developing predictive models for treatment response using massive multi-omic and clinical data
Gut Microbiome
Conducting multi-phase preclinical and clinical studies in patients diagnosed with schizophrenia to evaluate the impact of gut bacteria and prebiotics
THE TEAM LEAD
Dr. Daniel Mueller, MD PhD
Dr. Mueller is Head of the Pharmacogenetics Research Clinic at CAMH which is one of the first of its kind worldwide to implement pharmacogenetics in clinical practice for antidepressant and antipsychotic medications. Dr. Mueller is actively involved in developing pharmacogenetics treatment recommendations for physicians and patients through his close collaboration with international organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), the International Society of Psychiatric Genetics (ISPG) and the Pharmacogenetics Research Network (PGRN).
RECENT TALKS
RECENT PUBLICATIONS
JULY 2023
ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-Analysis Including Results from the CAN-BIND-1 Study
Magarbeh L, Hassel C, Choi M, Islam F, Marshe VS, Zai CC, Zuberi R, Gammal RS, Men X, Scherf-Clavel M, Enko D, Frey BN, Milev R, Soares CN, Parikh SV, Placenza F, Strother SC, Hassel S, Taylor VH, Leri F, … Müller DJ.
APRIL 2023
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study
Yoshida K, Marshe VS, Elsheikh SSM, Maciukiewicz M, Tiwari AK, Brandl EJ, Lieberman JA, Meltzer HY, Kennedy JL & Müller DJ.
APRIL 2023
Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study
Men X, Marshe V, Elsheikh SS, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Rothschild AJ, Voineskos AN, Whyte EM, Kennedy JL, Flint AJ & Müller DJ.
SEPTEMBER 2022
Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study
Islam F, Marshe VS, Magarbeh L, Frey BN, Milev RV, Soares CN, Parikh SV, Placenza F, Strother SC, Hassel S, Taylor VH, Leri F, Blier P, Uher R, Farzan F, Lam RW, Turecki G, Foster JA, Rotzinger S, Kennedy SH, … Müller DJ.
AFFILIATES & FUNDING
Pharmacogenetics Research Clinic,
Centre for Addiction and Mental Health
250 College Street
Toronto ON
CANADA M5T 1R8